- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT06765850
The Study Aims to Measure the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography and to Analyse Differences Depending on the Course of the Disease.
Measurement of the Metabolome in Melanoma Patients Using NMR Spectroscopy and Gas Chromatography.
Prospective, single-centre study with the central question of how the metabolome from blood samples, different body fluids and tissues between patients patients with malignant melanoma in different tumour tumour stages and healthy patients and whether this is suitable for early detection of initial diagnosis, recurrence or stage shift at an early stage.
The biosamples are collected in the BioBank Dresden and used for the NMR and LC-MS analyses described here. It is planned to use the biosamples for further analyses.
Study Overview
Status
Conditions
Study Type
Enrollment (Estimated)
Contacts and Locations
Study Contact
- Name: Frank Friedrich Gellrich, Dr. med.
- Phone Number: +493514582497
- Email: frankfriedrich.gellrich@ukdd.de
Study Locations
-
-
Saxony
-
Dresden, Saxony, Germany, 01307
- Recruiting
- University Hospital Carl Gustav Carus
-
Contact:
- Frank Friedrich Gellrich, Dr. med.
- Phone Number: +493514582497
- Email: frankfriedrich.gellrich@ukdd.de
-
Contact:
- Frank Friedrich Gellrich, Dr. med.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
- Older Adult
Accepts Healthy Volunteers
Sampling Method
Study Population
Description
Inclusion Criteria:
- Current or past history of melanoma
- Ongoing therapy or tumour aftercare at the Skin Cancer Centre at Dresden University Hospital
Exclusion Criteria:
- Refusal to participate in the study
- Lack of capacity to consent
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Differences in metabolite concentrations
Time Frame: through study completion, an average of 3 years
|
Metabolite concentrations are measured by NMR spectroscopy and gas chromatography and compared between different subgroups.
|
through study completion, an average of 3 years
|
Collaborators and Investigators
Sponsor
Collaborators
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- Melanomix
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.